Drug shows promising results for obese with pre-diabetes

08/24/2011 | Medscape (free registration)

Obese patients with pre-diabetes who took the experimental drug GFT505 had a 24.8% reduction in fasting plasma triglyceride levels, a 9.3% increase in HDL cholesterol and an 8.7% reduction in total cholesterol, a study in Diabetes Care found. The findings suggest that the new compound may help cut the risks of heart disease by decreasing insulin resistance and liver complications in such patients, the lead researcher said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA